254762-27-1
254762-27-1
Chemical Structure
4'-Hydroxy diclofenac-d4
- CAS No.: 254762-27-1
- Formula:C14H7D4Cl2NO3
- Molecular Weight:316.17
IUPAC Name: 2-(2-((2,6-dichloro-4-hydroxyphenyl)amino)phenyl-3,4,5,6-d4)acetic acid
InChIKey: KGVXVPRLBMWZLG-RHQRLBAQSA-N
SMILES: ClC(C=C(C=C1Cl)O)=C1NC2=C(C([2H])=C([2H])C([2H])=C2[2H])CC(O)=O
Biological Activity: 4'-Hydroxy diclofenac-d4 is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
4'-Hydroxy diclofenac-d4 | 99.77% | 4'-Hydroxy diclofenac-d4 is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4'-Hydroxy diclofenac (Standard) | ≥98% | 4'-Hydroxy diclofenac (Standard) is the analytical standard of 4'-Hydroxy diclofenac. This product is intended for research and analytical applications. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4'-Hydroxy diclofenac-13C6 | 99.21% | 4'-Hydroxy diclofenac-13C6 is the 13C labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4'-Hydroxy diclofenac | 99.70% | 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac methyl ester | 98.04% | Diclofenac methyl ester is a metabolite of Diclofenac (HY-15036), which exhibits acute cytotoxicity with a LC50 of 0.5 mg/L in H. azteca. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Meclofenamic acid-d4 | Meclofenamic acid-d4 is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Hydroxydiclofenac | 99.52% | 5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4',5-Dihydroxy Diclofenac-13C6 | 4',5-Dihydroxy Diclofenac- |
|||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac | 99.92% | Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac diethylamine | 99.95% | Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac diethylamine induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac-d4 | 99.02% | Diclofenac-d4 is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac-13C6 | 99.90% | Diclofenac-13C6 is the 13C6 labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac Sodium | 99.81% | Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac-d4 sodium | 99.49% | Diclofenac-d4 (sodium) is the deuterium labeled Diclofenac sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac-13C6 sodium | 99.96% | Diclofenac-13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diclofenac potassium | 99.85% | Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolfenamic acid-d4 | Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aceclofenac-d4 | Aceclofenac-d4 is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Flufenamic acid-d4 | Flufenamic acid-d4 is deuterium labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. J Shimamoto, et al. Lack of Differences in Diclofenac (A Substrate for CYP2C9) Pharmacokinetics in Healthy Volunteers With Respect to the Single CYP2C9*3 Allele. Eur J Clin Pharmacol. 2000 Apr;56(1):65-8. [Content Brief]
